🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Manitoba buys COVID-19 vaccine candidate, first province to bypass Ottawa

Published 2021-02-11, 04:32 p/m
© Reuters. FILE PHOTO: A woman holds a medical syringe and a small bottle labelled "Coronavirus COVID-19 Vaccine
PGR
-
PFE
-

By Rod Nickel

WINNIPEG, Manitoba (Reuters) - Manitoba said on Thursday it will buy 2 million doses of a COVID-19 vaccine candidate now in early trials, becoming the first Canadian province to bypass the national government.

The provincial government bought the doses from Alberta-based Providence Therapeutics, Premier Brian Pallister said. The company is developing a candidate similar to those produced by Pfizer Inc (NYSE:PFE) and Moderna Inc.

Alberta's premier also said his government is pursuing vaccine supplies because of federal delays procuring doses internationally.

If approved by the regulator, Health Canada, Providence would supply Manitoba with its first 200,000 doses late this year at the earliest. Pallister did not release financial terms.

Asked if the federal government had concerns about provinces buying their own supplies, Procurement Minister Anita Anand said Ottawa has never prevented them from doing so.

In total, Manitoba will buy 2 million doses for the province of 1.4 million people. Emergent BioSolutions would fill vials at its Winnipeg plant, but the doses will be manufactured by another company, Emergent spokeswoman Assal Hellmer said.

Pallister, a Progressive (NYSE:PGR) Conservative, has criticized Liberal Prime Minister Justin Trudeau, saying he has not delivered vaccines fast enough.

Canada's rate of vaccination lags behind rates per capita in the United States, the United Kingdom and other countries, but the number of new infections is dropping amid widespread restrictions.

"Canada first is in danger of becoming Canada last," Pallister said. "I just want a Canadian home-field advantage for us."

Alberta Premier Jason Kenney said he has contacted other premiers to establish an inter-provincial task force on vaccine supply.

Kenney said Providence told him it would need a C$150 million order representing 50 million doses to establish a Canadian production facility.

Ottawa has signed all other vaccine procurement deals so far but they are all made outside Canada and only Pfizer and Moderna have regulatory approval. The provinces are in charge of administering vaccines.

Last week, Canada signed its first deal to allow a foreign coronavirus vaccine, developed by Novavax Inc, to be manufactured domestically.

© Reuters. FILE PHOTO: A woman holds a medical syringe and a small bottle labelled

(This story corrects paragraph six to say "doses will be manufactured by another company" instead of "Emergent BioSolutions would manufacture the doses")

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.